Two diabetes research giants, Ralph DeFronzo, MD, and David Nathan, MD, faced off on whether to use initial combination therapy versus starting with metformin and adding more medications sequentially.
Engraftment of Vertex Pharmaceutical s VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.
In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development.
Higher doses of oral semaglutide (25 mg and 50 mg) seem to be effective in type 2 diabetes and obesity, improving upon results obtained with currently approved maximum dose of oral semaglutide 14 mg daily.